Literature DB >> 5570752

Hemolytic assay of the ninth complement complement component: elevation and depletion in rheumatic diseases.

S Ruddy, L K Everson, P H Schur, K F Austen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5570752

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


× No keyword cloud information.
  12 in total

1.  Immunoglobulins and complement components in synovial fluid of patients with acute rheumatic fever.

Authors:  M Svartman; E V Potter; T Poon-King; D P Earle
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

2.  The complement system in bullous pemphigoid. I. Complement and component levels in sera and blister fluids.

Authors:  R E Jordon; N K Day; W M Sams; R A Good
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

3.  Complement metabolism in the seronegative arthritides.

Authors:  K Whaley; B Canesi; A Moseley; W Morrow; R Sturrock; W Mitchell; W C Dick
Journal:  Ann Rheum Dis       Date:  1974-11       Impact factor: 19.103

4.  Immunological properties of isolated IgG and IgM anti-gamma-globulins (rheumatoid factors).

Authors:  N E Bianco; L W Dobkin; P H Schur
Journal:  Clin Exp Immunol       Date:  1974-05       Impact factor: 4.330

5.  Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9.

Authors:  R G DiScipio; M R Gehring; E R Podack; C C Kan; T E Hugli; G H Fey
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

6.  Complement metabolism in rheumatoid arthritis. I. Longitudinal studies.

Authors:  J M Versey; J R Hobbs; P J Holt
Journal:  Ann Rheum Dis       Date:  1973-11       Impact factor: 19.103

7.  Erythropoietic protoporphyria. Photoactivation of the complement system.

Authors:  I Gigli; A A Schothorst; N A Soter; M A Pathak
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

8.  C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

9.  C2 deficiency. Development of lupus erythematosus.

Authors:  N K Day; H Geiger; R McLean; A Michael; R A Good
Journal:  J Clin Invest       Date:  1973-07       Impact factor: 14.808

10.  Cutaneous necrotizing venulitis: a sequential analysis of the morphological alterations occurring after mast cell degranulation in a patient with a unique syndrome.

Authors:  N A Soter; M C Mihm; H F Dvorak; K F Austen
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.